- Home
- Primary Care
- Long-Acting Monoclonal Antibodies in RSV: Nirsevimab and Beyond
5mo3 min read
Medical Article
Respiratory syncytial virus (RSV) is one of the most common causes of acute lower respiratory infections in children globally and contributes significantly to severe respiratory disease in elderly persons (1). Each year, RSV causes an estimated 3.6 million hospitalizations and approximately 100,000 deaths in children under 5 years of age (1,2). App

Long-Acting Monoclonal Antibodies in RSV: Nirsevimab and Beyond
2605 Reached31 Comments
Similar Content

Woman presented with Fever of Unknown Origin
7731 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35339 Reached151 Comments202 Likes

Rubella Syndrome in Neonate
1401 Reached12 Comments9 Likes

Pregnant Woman with HIV-1 Infection
747 Reached1 Likes

Use of Clindamycin for Managing Bacterial Vaginosis
11214 Reached29 Comments8 Likes
